arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Jade Biosciences, Inc.

JBIO Health Care Biotechnology: Pharmaceutical Preparations
$19.90
Today
as of Sep 4, 16:50 ET
Last 30 days +1.02% Jul 28 → Sep 04
$18.71 $20.32 $21.93 $23.54 $25.15 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$19.86
High
$20.35
Low
$19.70
Volume
$605,018
Avg Vol
$559,076
Mkt Cap
$1.4B
P/E (TTM)
—
Beta
—
52w High
$28.00
52w Low
$6.91
Div Yield
—
Shares Out
$64M

Recent Press Releases & News last 60 days · 3 items

Sep 1 · 11:00 PR GlobeNewswire
Jade Biosciences to Participate in Upcoming Conferences
Aug 10 · 15:43 MT Newswires
Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating
Aug 10 · 11:25 MT Newswires
Jade Biosciences' Q2 Loss Narrows

Overview

52-week range
$6.91
$28
62% of range
Avg surprise (last 3)
-13.2%
Avg reaction (last 2)
-2.5%
0% positive
Latest IV / EM
111%
EM ±18.0% · $20 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-5.16$-3.89$-2.62$-1.36$-0.09 Actual $-0.67Actual $-0.76Actual $-0.71Actual $-0.83Actual $-0.86Actual $-5.16Actual $-0.09Est $-0.30Actual $-0.86Est $-0.43Actual $-0.48Actual $-0.57Est $-0.52Actual $-0.76 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-56M$-46M$-36M$-27M$-17M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.76 — — — — financials
Thu May 7, 2026Mar/2026 $-0.57 $-0.52 -9.6% -533.3% -3.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.48 — — — — financials
Wed Aug 13, 2025Jun/2025 $-0.86 $-0.43 -100.0% — — earnings
Fri Apr 25, 2025Mar/2025 $-0.09 $-0.30 +70.0% — -1.5% earnings
Mon Sep 30, 2024Sep 2024 $-5.16 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.86 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.83 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.71 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.76 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.67 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-59M$-43M—$-27M$-28M$-23M—$-15M
Net income$-56M$-40M—$-25M$-32M$-38M—$-16M
EPS (diluted)$-0.76$-0.57—$-0.48$-0.86$-12.10—$-5.16

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$107M$55M$88M$50M$221M$44M$69M$31M
Inventory————————
Total current assets$471M$319M$349M$201M$223M$77M$70M$91M
Total assets$472M$319M$350M$202M$224M$78M$73M$91M
Long-term debt————————
Total liabilities$32M$23M$17M$23M$22M$2M$120M$10M
Total equity$440M$296M$333M$179M$202M$-84M$-47M$-17M

Implied volatility — last 90 days

58%221%385%549%712% Jun 08 — IV 263% · EM ±34.7%Jun 10 — IV 277% · EM ±32.8%Jun 16 — IV 523% · EM ±30.9%Jun 17 — IV 713% · EM ±29.8%Jun 22 — IV 108% · EM ±22.6%Jun 23 — IV 116% · EM ±23.7%Jun 24 — IV 115% · EM ±23.0%Jun 25 — IV 127% · EM ±24.9%Jun 26 — IV 119% · EM ±22.7%Jun 29 — IV 128% · EM ±22.6%Jun 30 — IV 131% · EM ±22.5%Jul 01 — IV 137% · EM ±22.9%Jul 02 — IV 155% · EM ±25.1%Jul 03 — IV 161% · EM ±25.1%Jul 06 — IV 169% · EM ±23.5%Jul 07 — IV 178% · EM ±23.5%Jul 09 — IV 188% · EM ±22.2%Jul 10 — IV 216% · EM ±23.9%Jul 13 — IV 304% · EM ±25.4%Jul 14 — IV 324% · EM ±23.4%Jul 15 — IV 387% · EM ±22.9%Jul 20 — IV 121% · EM ±28.5%Jul 21 — IV 107% · EM ±24.8%Jul 22 — IV 98% · EM ±22.4%Jul 24 — IV 114% · EM ±25.1%Jul 27 — IV 122% · EM ±25.6%Jul 28 — IV 127% · EM ±25.9%Jul 29 — IV 132% · EM ±26.4%Jul 30 — IV 119% · EM ±23.4%Jul 31 — IV 134% · EM ±25.6%Aug 03 — IV 149% · EM ±26.4%Aug 04 — IV 163% · EM ±28.1%Aug 05 — IV 143% · EM ±24.0%Aug 06 — IV 139% · EM ±22.5%Aug 10 — IV 166% · EM ±23.0%Aug 11 — IV 169% · EM ±22.4%Aug 12 — IV 180% · EM ±22.6%Aug 13 — IV 165% · EM ±19.5%Aug 14 — IV 183% · EM ±20.2%Aug 17 — IV 255% · EM ±21.3%Aug 18 — IV 294% · EM ±21.2%Aug 19 — IV 212% · EM ±12.5%Aug 20 — IV 620% · EM ±25.9%Aug 24 — IV 122% · EM ±25.4%Aug 25 — IV 58% · EM ±11.9%Aug 26 — IV 126% · EM ±25.3%Aug 27 — IV 129% · EM ±25.4%Aug 28 — IV 81% · EM ±15.5%Aug 31 — IV 132% · EM ±23.4%Sep 01 — IV 141% · EM ±24.3%Sep 02 — IV 140% · EM ±23.4%Sep 03 — IV 111% · EM ±18.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in